Skip to main content

Signed · Netherlands · Medical technology

EQT agrees to acquire QIAGEN.

A bid vehicle controlled by the EQT XI fund (Stockholm, Sweden) signed a business combination agreement with Venlo-based sample and molecular diagnostics group QIAGEN on 21 October 2026, under which it will make a recommended all-cash public offer of EUR 46.50 per share. Closing is expected in mid-2027. It was signed on 21 October 2026. It had not completed by 28 October 2026.

SigningDay 100

Signing 21 October 2026

Buyer
EQT AB ·Stockholm, Sweden
Target
QIAGEN N.V. ·Venlo, Netherlands
Type
Acquisition
Announced
21 October 2026
Signed
21 October 2026
Value
EUR 10.8 billion
People
Not stated in the release
Last checked
28 October 2026

The people side in the Netherlands

Related deals

Get the briefing

Deals into Europe lists public facts with their sources, checked every working day by Octagon Professionals International. Corrections go to info@octagon.nl and are made within one working day. How we track deals.

Enabling organisations to operate across borders with clarity, compliance, and trust.

All deals into Europe